Related Experiment Video

Updated: Jun 4, 2026

An Adipocyte Cell Culture Model to Study the Impact of Protein and Micro-RNA Modulation on Adipocyte Function
09:20

An Adipocyte Cell Culture Model to Study the Impact of Protein and Micro-RNA Modulation on Adipocyte Function

Published on: May 4, 2021

Tumor progression locus 2 (TPL2) regulates obesity-associated inflammation and insulin resistance

James W Perfield1, Yunkyoung Lee, Gerald I Shulman

  • 1Obesity and Metabolism Laboratory, JM-USDA Human Nutrition esearch Center on Aging, Tufts University, Boston, Massachusetts, USA.

Diabetes
|February 25, 2011
PubMed
Abstract

Insights

Deleting Tumor Progression Locus 2 (TPL2) kinase in mice improves insulin sensitivity and reduces inflammation in obesity. This suggests TPL2 is a potential therapeutic target for metabolic dysfunction.

Area of Science:

  • Metabolic disease research
  • Inflammation and immunology
  • Molecular biology

Background:

  • Obesity causes low-grade systemic inflammation, linked to insulin resistance and type 2 diabetes.
  • Targeting inflammatory pathways can improve metabolic health in obesity.
  • Tumor progression locus 2 (TPL2) is a kinase regulating inflammatory signaling.

Purpose of the Study:

  • To investigate the role of TPL2 in obesity-associated inflammation and insulin resistance.
  • To determine if TPL2 deletion impacts metabolic dysfunction in diet-induced obesity.

Main Methods:

  • Male TPL2 knockout (KO) and wild-type (WT) mice were fed high-fat diets.
  • Insulin sensitivity was assessed using hyperinsulinemic euglycemic clamp studies.
  • Inflammation markers and gene expression in adipose tissue and liver were analyzed.

Main Results:

  • TPL2 deletion did not affect body or adipose tissue weight.
  • Obese TPL2 KO mice showed improved insulin sensitivity and glucose uptake.
  • Reduced inflammation and lipid accumulation were observed in the adipose tissue and liver of obese TPL2 KO mice.

Conclusions:

  • TPL2 ablation attenuates obesity-associated metabolic dysfunction in vivo.
  • TPL2 is identified as a novel therapeutic target for improving obesity-related metabolic complications.

More Related Videos

Generation of High Quality Chromatin Immunoprecipitation DNA Template for High-throughput Sequencing (ChIP-seq)09:52

Generation of High Quality Chromatin Immunoprecipitation DNA Template for High-throughput Sequencing (ChIP-seq)

Published on: April 19, 2013

Differentiated Mouse Adipocytes in Primary Culture: A Model of Insulin Resistance09:48

Differentiated Mouse Adipocytes in Primary Culture: A Model of Insulin Resistance

Published on: February 17, 2023

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...
Type II Diabetes I: Introduction01:26

Type II Diabetes I: Introduction

Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder characterized by insulin resistance, in which target tissues such as the liver, muscle, and adipose tissue respond poorly to insulin. It is also associated with inadequate compensatory insulin secretion, where pancreatic β-cells fail to produce sufficient insulin. Together, these abnormalities lead to persistent hyperglycemia.EtiologyT2DM develops through a complex interaction of genetic predisposition and environmental or...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
Tumor Progression02:07

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...